Service Description

The CA 27.29 (BR) test measures the level of the CA 27.29 protein in the blood, which can be elevated in certain breast conditions. It is primarily used to monitor treatment and detect recurrence in patients with breast cancer. Why it’s done: To monitor treatment response in breast cancer patients To help detect recurrence of breast cancer Occasionally used alongside other tests to evaluate breast-related abnormalities Not typically used as a standalone screening test Specimen Type: Blood draw Turnaround Time: Typically 1–3 business days Collection Available: In-office or mobile blood draw services